Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 1;119(9):1981-7.
doi: 10.1182/blood-2011-08-358135. Epub 2012 Jan 6.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop Kantarjian  1 , Susan O'Brien, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, Jenny Shan, Mary Beth Rios, Farhad Ravandi, Stefan Faderl, Tapan Kadia, Gautam Borthakur, Xuelin Huang, Richard Champlin, Moshe Talpaz, Jorge Cortes
Affiliations

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

Hagop Kantarjian et al. Blood. .

Abstract

A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP. In CP, the 8-year survival was ≤ 15% before 1983, 42%-65% from 1983-2000, and 87% since 2001. Survival was worse in older patients (P = .004), but this was less significant since 2001 (P = .07). Survival by Sokal risk was significantly different before 2001 (P < .001), but not since 2001 (P = .4). In AP, survival improved over time (P < .001); the 8-year survival in patients treated since 2001 was 75%. Survival by age was not different in years < 2001 (P = .09), but was better since 2001 in patients ≤ 70 years of age (P = .004). In BP, the median survival improved over time (P < .001), although it has been only 7 months since 2001. In summary, survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML. Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival in newly diagnosed CP-CML by year of therapy.
Figure 2
Figure 2
Survival in newly diagnosed CP-CML. (A) By age before 1983 overall, (B) from 1983-2000, and (C) since 2001.
Figure 3
Figure 3
Survival in newly diagnosed CP-CML. (A) By Sokal risk factor before 1983, (B) from 1983-2000, and (C) since 2001.
Figure 4
Figure 4
Survival in AP-CML. (A) By year of therapy and (B) by age since 2001.
Figure 5
Figure 5
Survival in BP-CML. (A) By year of therapy and (B) by age since 2001.
Figure 6
Figure 6
Survival after allogeneic SCT. (A) By phase of CML at the time of SCT and (B) by year of therapy in CP.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Druker B, Guilhot F, O'Brien S, Gathman I, Kantarjian H, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–17. - PubMed
    1. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108(6):1835–1840. - PubMed
    1. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108(5):1478–1484. - PubMed
    1. Kantarjian H, O'Brien S, Cortes J, et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon alpha regimens for early chronic phase. Cancer. 2003;98(7):1430–7. - PubMed
    1. Walters R, Kantarjian H, Keating M, et al. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer. 1987;60(8):1708–1712. - PubMed

Publication types

MeSH terms